Sunshine Biopharma Inc. (SBFM)

Nasdaq: SBFM · Pharmaceutical Preparations · Fort Lauderdale, FL · filing with the SEC since 2007

Full chart Alerts Compare

Grade4.7

◀ Past 3.6● Present 5.8▶ Future 4.2

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$36.3M+4.1%

Net income-$6.0M-16.4%

Earnings per share$-1.44+80.3%

Operating cash flow-$5.3M+57.4%

Cash$9.1M-5.8%

Debtn/a

Shareholders’ equity$23.0M-2.0%

Shares, diluted4,157,086+492.4%

Return on equity-25.9%

The recordfrom its filings

Filings in 202657

Newest filingNov 12 · 10-Q

Annual reportApr 3, 2026

Quarterly reportNov 12, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted0

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $35.4MNet income -$6.2MCash from operations -$6.0Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 12, 2026 · SEC EDGAR · Form DEF 14A

Proxy statement

Open the filing on sec.gov

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 27, 2026 · SEC EDGAR · Form DEF 14C

Information statement

Open the filing on sec.gov

Oct 14, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Oct 14, 2026 · SEC EDGAR · Form PRE 14C

Preliminary information statement

Open the filing on sec.gov

Oct 14, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Oct 9, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 9, 2026 · SEC EDGAR · Form 424B4

Offering prospectus

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Sunshine Biopharma Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Fort Lauderdale, FL.

Newest on the record

Quarterly report on Nov 12. Before it, proxy statement on Nov 12.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About SBFM

Sunshine Biopharma Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Fort Lauderdale, FL. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $36 million and a loss of $6.0 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersFort Lauderdale, FL

Business modelProduct business

ExchangeNasdaq, Nasdaq

Filing since2007

Fiscal year endsDec 31

SEC number (CIK)1402328

Peers on fileBFRI, EQ, CUE, VRCA

Who runs it

Financial performance

In fiscal 2025 Sunshine Biopharma’s revenue was $36.31 million, up 4.1% from $34.87 million the year before. It made a net loss of $5.98 million.

Annual report, filed Apr 3, 2026.

Financial statements

The grade

Sunshine Biopharma grades 4.7 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past3.6

● Present5.8

▶ Future4.2

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton SBFM · research, not advice